Patents by Inventor Ulla Mandel
Ulla Mandel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11860165Abstract: The present inventors have demonstrated that circulating auto-antibodies to cancer antigens hold promise as specific and sensitive biomarkers for the early detection of cancer. The present invention thus relates to methods of detecting cancer in a sample, comprising utilising a glycopeptide bait derived from human mucins with different cancer-associated O-glycans. Detected antibodies were demonstrated as glycopeptide specific, and it could be discriminated between e.g. colorectal cancer patients and healthy individuals. The inventors have also developed monoclonal antibodies based on the identified glycopeptides epitope baits, and demonstrated differential expression of the relevant target antigens. The invention thus, in a lock and key-based manner includes both glycopeptides and antibody tools for early detection of cancer, as well as methods of using the same for in situ visualisation and treatment of specific cancer types.Type: GrantFiled: June 18, 2021Date of Patent: January 2, 2024Assignee: GO Therapeutics, Inc.Inventors: Hans H. Wandall, Johannes Wirenfeldt Vad Pedersen, Eric Paul Bennett, Henrik Clausen, Ulla Mandel
-
Publication number: 20220065862Abstract: The present inventors have demonstrated that circulating auto-antibodies to cancer antigens hold promise as specific and sensitive biomarkers for the early detection of cancer. The present invention thus relates to methods of detecting cancer in a sample, comprising utilising a glycopeptide bait derived from human mucins with different cancer-associated O-glycans. Detected antibodies were demonstrated as glycopeptide specific, and it could be discriminated between e.g. colorectal cancer patients and healthy individuals. The inventors have also developed monoclonal antibodies based on the identified glycopeptides epitope baits, and demonstrated differential expression of the relevant target antigens. The invention thus, in a lock and key-based manner includes both glycopeptides and antibody tools for early detection of cancer, as well as methods of using the same for in situ visualisation and treatment of specific cancer types.Type: ApplicationFiled: June 18, 2021Publication date: March 3, 2022Applicant: GO THERAPEUTICS, INC.Inventors: Hans H. Wandall, Johannes Wirenfeldt Vad Pedersen, Eric Paul Bennett, Henrik Clausen, Ulla Mandel
-
Patent number: 11067578Abstract: The present inventors have demonstrated that circulating auto-antibodies to cancer antigens hold promise as specific and sensitive biomarkers for the early detection of cancer. The present invention thus relates to methods of detecting cancer in a sample, comprising utilising a glycopeptide bait derived from human mucins with different cancer-associated O-glycans. Detected antibodies were demonstrated as glycopeptide specific, and it could be discriminated between e.g. colorectal cancer patients and healthy individuals. The inventors have also developed monoclonal antibodies based on the identified glycopeptides epitope baits, and demonstrated differential expression of the relevant target antigens. The invention thus, in a lock and key-based manner includes both glycopeptides and antibody tools for early detection of cancer, as well as methods of using the same for in situ visualisation and treatment of specific cancer types.Type: GrantFiled: October 16, 2018Date of Patent: July 20, 2021Assignee: GO Therapeutics, Inc.Inventors: Hans H. Wandall, Johannes Wirenfeldt Vad Pedersen, Eric Paul Bennett, Henrik Clausen, Ulla Mandel
-
Patent number: 10919973Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.Type: GrantFiled: June 12, 2018Date of Patent: February 16, 2021Assignees: KOBENHAVNS UNIVERRSITET, CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
-
Publication number: 20190330601Abstract: The present invention relates to a method for display of a plurality of mammalian glycans on cells or proteins for probing biological interactions and identifying glycan structures involved. A plurality of mammalian cells is genetically engineered in a combinatorial approach to differentially express the human glycome. Genetic engineering of the cell produces a plurality isogenic cells with different repertoires of glycosyltransferases and display of glycans that is used to interpret biological interactions. The plurality of engineered cells display glycans with and without the context of specific proteins exogeneously expressed, and is useful for detection and optimization of biological interactions for example binding of lectins, antibodies, viruses and bacteria and glycoproteins.Type: ApplicationFiled: May 11, 2017Publication date: October 31, 2019Inventors: Eric BENNETT, Yoshiki NARIMATSU, Catharina STEENTOFT, Zhang YANG, Ulla MANDEL, Henrik CLAUSEN
-
Publication number: 20190101541Abstract: The present inventors have demonstrated that circulating auto-antibodies to cancer antigens hold promise as specific and sensitive biomarkers for the early detection of cancer. The present invention thus relates to methods of detecting cancer in a sample, comprising utilising a glycopeptide bait derived from human mucins with different cancer-associated O-glycans. Detected antibodies were demonstrated as glycopeptide specific, and it could be discriminated between e.g. colorectal cancer patients and healthy individuals. The inventors have also developed monoclonal antibodies based on the identified glycopeptides epitope baits, and demonstrated differential expression of the relevant target antigens. The invention thus, in a lock and key-based manner includes both glycopeptides and antibody tools for early detection of cancer, as well as methods of using the same for in situ visualisation and treatment of specific cancer types.Type: ApplicationFiled: October 16, 2018Publication date: April 4, 2019Applicant: GO THERAPEUTICS, INC.Inventors: Hans H. Wandall, Johannes Wirenfeldt Vad Pedersen, Eric Paul Bennett, Henrik Clausen, Ulla Mandel
-
Patent number: 10139414Abstract: The present inventors have demonstrated that circulating auto-antibodies to cancer antigens hold promise as specific and sensitive biomarkers for the early detection of cancer. The present invention thus relates to methods of detecting cancer in a sample, comprising utilising a glycopeptide bait derived from human mucins with different cancer-associated O-glycans. Detected antibodies were demonstrated as glycopeptide specific, and it could be discriminated between e.g. colorectal cancer patients and healthy individuals. The inventors have also developed monoclonal antibodies based on the identified glycopeptides epitope baits, and demonstrated differential expression of the relevant target antigens. The invention thus, in a lock and key-based manner includes both glycopeptides and antibody tools for early detection of cancer, as well as methods of using the same for in situ visualisation and treatment of specific cancer types.Type: GrantFiled: March 6, 2017Date of Patent: November 27, 2018Assignee: GO THERAPEUTICS, INC.Inventors: Hans H. Wandall, Johannes Wirenfeldt Vad Pedersen, Eric Paul Bennett, Henrik Clausen, Ulla Mandel
-
Publication number: 20180334507Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.Type: ApplicationFiled: June 12, 2018Publication date: November 22, 2018Inventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
-
Patent number: 10017576Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.Type: GrantFiled: February 10, 2016Date of Patent: July 10, 2018Assignees: Københavns Universitet, Cancer Research Technology LimitedInventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
-
Publication number: 20170322219Abstract: The present inventors have demonstrated that circulating auto-antibodies to cancer antigens hold promise as specific and sensitive biomarkers for the early detection of cancer. The present invention thus relates to methods of detecting cancer in a sample, comprising utilising a glycopeptide bait derived from human mucins with different cancer-associated O-glycans. Detected antibodies were demonstrated as glycopeptide specific, and it could be discriminated between e.g. colorectal cancer patients and healthy individuals. The inventors have also developed monoclonal antibodies based on the identified glycopeptides epitope baits, and demonstrated differential expression of the relevant target antigens. The invention thus, in a lock and key-based manner includes both glycopeptides and antibody tools for early detection of cancer, as well as methods of using the same for in situ visualisation and treatment of specific cancer types.Type: ApplicationFiled: March 6, 2017Publication date: November 9, 2017Inventors: Hans H. Wandall, Johannes Wirenfeldt Vad Pedersen, Eric Paul Bennett, Henrik Clausen, Ulla Mandel
-
Publication number: 20160176975Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.Type: ApplicationFiled: February 10, 2016Publication date: June 23, 2016Inventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
-
Patent number: 9359436Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.Type: GrantFiled: November 12, 2014Date of Patent: June 7, 2016Assignees: Københavns Universitet, Cancer Research Technology LimitedInventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
-
Publication number: 20150065692Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.Type: ApplicationFiled: November 12, 2014Publication date: March 5, 2015Inventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
-
Patent number: 8912311Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.Type: GrantFiled: April 16, 2013Date of Patent: December 16, 2014Assignees: Københavns Universitet, Cancer Research Technology LimitedInventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
-
Publication number: 20140005366Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.Type: ApplicationFiled: April 16, 2013Publication date: January 2, 2014Applicants: Cancer Research Technology Limited, Københavns UniversitetInventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
-
Patent number: 8440798Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.Type: GrantFiled: October 4, 2007Date of Patent: May 14, 2013Assignees: Københavns Universitet, Cancer Research Technology LimitedInventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
-
Publication number: 20100034825Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.Type: ApplicationFiled: October 4, 2007Publication date: February 11, 2010Applicants: Kobenhavns Universitet, Cancer Research Tecnology LimitedInventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sorensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
-
Patent number: 5227160Abstract: Monoclonal antibody NUH2 produced by a hybridoma having ATCC deposit no. HB 9762. An isolated antigen capable of specifically binding to anti-human sperm antibodies including NUH2 and comprising at least an epitope having a sialyl I structure, and any analogues derived from said antigen. Methods of using the monoclonal antibody and antigen for contraception and treating infertility in human females.Type: GrantFiled: July 15, 1988Date of Patent: July 13, 1993Assignees: The Biomembrane Institute, Hyogo Medical CollegeInventors: Edward Nudelman, Tokio Kaizu, Ulla Mandel-Clausen, Steven B. Levery, Sen-itiroh Hakomori, Yoshiyuki Tsuji, Shinzo Isojima